A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
Status:
Recruiting
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety of Vemurafenib in combination with
Metformin in melanoma patients. The phase II part of the study will also evaluate the
clinical activity of the combined regiment. Based on pre-clinical studies and a phase I
trial, the investigators hypothesize that the combination of an FDA-approved non-toxic dose
of oral Metformin with Vemurafenib will yield little toxicity and improve clinical outcomes
in terms of objective response rates and survival in metastatic melanoma patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
James Graham Brown Cancer Center University of Louisville
Collaborators:
James Graham Brown Cancer Center University of Louisville